Article | December 2, 2022

Longhorn's Path To A Universal Influenza Vaccine

Source: Cytiva
GettyImages-1311518492-vaccine-vial

In 2005, renowned pediatric and infectious disease researcher, Dr. Gerald Fischer founded Longhorn Vaccines & Diagnostics in partnership with his son, Jeff Fischer. After considering the medical needs of the near future, they set out to develop both diagnostic and vaccine products aimed at preventing and mediating an influenza pandemic. They began work on a universal flu vaccine while focusing their remaining resources towards creating tools to diagnose early-stage pandemic influenza.

At the onset of the COVID-19 pandemic, their work was proven vital. Longhorn went from producing 50,000 units of their diagnostic product to 50 million units to support the demand of the pandemic. And now, after 17 years of work, they are preparing their universal influenza vaccine for clinical trials. Thanks to a longstanding and fruitful collaboration with the U.S. Army, Longhorn is partnering with the Walter Reed National Military Medical Center to utilize their adjuvant in the vaccine as well as their cutting edge clinical trial sites.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Biosimilar Development